Monitor the effectiveness of TNF alpha inhibitors adalimumab, infliximab, and etanercept with one automated, cost-effective, and easily accessible assay
The N Latex aTNFα assay1 for use on Atellica® NEPH 630,1 BN™ II, and BN ProSpec® Systems is designed to quantify adalimumab, infliximab, and etanercept in human serum. It is an automated, cost-effective assay that enables physicians to make decisions on optimizing the effectiveness of therapeutic anti-inflammatory medication regimens.
Features & Benefits
Flexible assay. Few steps. Fast results.
The N Latex aTNFα assay1 from Siemens Healthineers provides:
Consolidated, random-access testing and streamlined workflow
One assay for quantification of three TNF-alpha inhibitors using individual calibrations
Fully automated testing for improved workflow
Individual or parallel determination of adalimumab, infliximab, and etanercept from different samples by providing separate assay protocols for each application
No need to pool samples
Economical testing and cost efficiency
Broad initial measuring range covering the therapeutic range of each substance that helps reduce the need for redilutions and supports economical reagent use
Separate calibrators and controls that enable cost-effective use of assay components
Ability to measure just one sample without wasting additional testing capacities
Improved patient management and clinical outcomes
Insight into response to and effectiveness of anti-inflammatory medication containing adalimumab, infliximab, and etanercept
Optimization of individual therapeutic dosage regimens for improved personalized patient management and therapy